Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|November 2, 2018
- Pharmaceutical Technology-11-02-2018
- Volume 42
- Issue 11
Bioimaging Molecular Probes
Stream Bio’s Conjugated Polymer Nanoparticle products are a new generation of novel molecular bioimaging probes for diagnostic and therapeutic applications.
Stream Bio’s Conjugated Polymer Nanoparticle (CPN) products are a new generation of novel molecular bioimaging probes for diagnostic and therapeutic applications. The highly fluorescent, non- toxic nanoparticles come in emission wavelengths 475, 510, 550, and 680 nm, covering colors blue, green, yellow, and red.
The products can be used in molecular imaging and R&D applications, including flow cytometry, enzyme-linked immunosorbent assay, fluorescent in situ hybridization, western blotting fluorescence resonance energy transfer, intensity-hue-saturation, and lateral flow assays.
The CPNs provide significant photostability and sensitivity (brightness) with highly specific targeting and magnetic cell-purification capability, while remaining compliant with existing lab protocols, the company reports.
Articles in this issue
almost 8 years ago
Guidelines on Integral Drug-Device Combinationsalmost 8 years ago
Detachable AODD Pumpalmost 8 years ago
Advanced Paddle Blender for Labsalmost 8 years ago
Custom Multi-Shaft Mixeralmost 8 years ago
User Requirements Specifications–How Difficult Can It Be?almost 8 years ago
Single-Use Bioprocessing Equipment Trends and Adoption by CMOsalmost 8 years ago
Innovations in Prefilled Syringes for Biologic Drugsalmost 8 years ago
Media Requirements for Different Cell SourcesRelated to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.